Headlands Technologies’s Akebia Therapeutics AKBA Stock Holding History

Headlands Technologies’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$67.6K	Buy	+48,658	New	+$66.9K	0.01%	686
2025 Q3	–	Sell	-1,254	Closed	-$4.57K	–	618
2025 Q2	$4.57K	Buy	+1,254	New	+$3.45K	﹤0.01%	1071
2024 Q3	–	Sell	-208	Closed	-$212	–	1162
2024 Q2	$212	Sell	208 -2,529	-92%	-$3.13K	﹤0.01%	1079
2024 Q1	$5.01K	Buy	+2,737	New	+$4.38K	﹤0.01%	1102

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Headlands Technologies's AKBA Position: Q1 2026 in Review

Headlands Technologies opened a new position in Akebia Therapeutics (AKBA) in Q1 2026: 48,658 shares worth $67.6K. The stake represents 0.01% of the portfolio and ranks #686 among its holdings. This is a return to the name: Headlands Technologies previously reported a position in AKBA as recently as Q2 2025.

Headlands Technologies first reported a position in AKBA in Q1 2024 and has held it in 4 quarters since. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

Headlands Technologies held 48,658 shares of Akebia Therapeutics worth $67.6K as of Q1 2026.
Akebia Therapeutics was a new Headlands Technologies position in Q1 2026.
Akebia Therapeutics made up 0.01% of Headlands Technologies's portfolio in Q1 2026, its #686 holding.
Headlands Technologies first reported a position in Akebia Therapeutics in Q1 2024 and has held it in 4 quarters since.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.